Complete Response Letter NDA 505b1 215644 (Oct 25, 2024)

Summary

This document outlines specific requirements for updating safety data in a New Drug Application (NDA), focusing on incorporating new clinical trial findings, adverse event reporting, and global safety information.

Key points

• Describe in detail any significant changes or findings in the safety profile.
• Incorporate new safety data into sections describing discontinuations due to adverse events, serious adverse events, and common adverse events.
• Present new safety data from studies/clinical trials for the proposed indication using the same format as in the original submission.
• Present tabulations of the new safety data combined with the original application data.
• Include tables that compare frequencies of adverse events in the original application with the retabulated frequencies.
• For indications other than the proposed indication, provide separate tables for the frequencies of adverse events occurring in clinical trials.
• Present a retabulation of the reasons for premature trial discontinuation by incorporating drop-outs from newly completed trials and describe any new trends or patterns identified.
• Provide case report forms and narrative summaries for each subject who died during a clinical trial or who did not complete a trial because of an adverse event.

Cited reasons

• Incomplete Adverse Event Reporting for Other Indications
• Missing Case Report Forms and Narratives for Serious Outcomes
• Missing Narrative Summaries for Serious Adverse Events
• Outdated Clinical Exposure Information
• Incomplete Worldwide Safety Summary
• Missing English Translations of Foreign Labeling
• The FDA issued a Complete Response Letter primarily due to significant deficiencies in the clinical safety data presentation and reporting. The agency requires more detailed and updated information regarding adverse events across all indications, comprehensive case report forms and narrative summaries for serious outcomes, updated clinical exposure data, a summary of worldwide safety experience, and English translations of foreign labeling.

Recommended actions

• Describe in detail any significant changes or findings in the safety profile.
• Incorporate new safety data into sections describing discontinuations due to adverse events, serious adverse events, and common adverse events.
• Present new safety data from studies/clinical trials for the proposed indication using the same format as in the original submission.
• Present tabulations of the new safety data combined with the original application data.
• Include tables that compare frequencies of adverse events in the original application with the retabulated frequencies.
• For indications other than the proposed indication, provide separate tables for the frequencies of adverse events occurring in clinical trials.
• Present a retabulation of the reasons for premature trial discontinuation by incorporating drop-outs from newly completed trials and describe any new trends or patterns identified.
• Provide case report forms and narrative summaries for each subject who died during a clinical trial or who did not complete a trial because of an adverse event.

Deficiency summary

The FDA issued a Complete Response Letter primarily due to significant deficiencies in the clinical safety data presentation and reporting. The agency requires more detailed and updated information regarding adverse events across all indications, comprehensive case report forms and narrative summaries for serious outcomes, updated clinical exposure data, a summary of worldwide safety experience, and English translations of foreign labeling.

Findings

Regulatory context

Submission stage

final decision

Regulatory pathway

NDA

Impact

Impact score

0.75

Estimated delay

270 days

Estimated rework cost

$0

Subsequent action

resubmission

Strategic insights

The primary theme of the Complete Response Letter is the inadequacy and incompleteness of the clinical safety data and reporting, requiring a substantial update and re-presentation of adverse event information, patient narratives, exposure data, and global safety experience, along with administrative labeling translations.

Regulatory change impact: Pending sponsor mitigation plan

Approval likelihood after response: 25%